



**ACTACC**  
Association for Cardiothoracic Anaesthesia  
and Critical Care

# Perioperative Vasoplegia in Cardiac Surgery National Audit

*Carlos Corredor, Sriveena Naganathar,  
Vivek Sharma, Benjamin Milne, Gudrun Kunst  
ACTACC Link Person Network*



**ACTACC**

Association for Cardiothoracic Anaesthesia  
and Critical Care

# Disclosures

- None relevant
- On behalf of the ACTACC Vasoplegia Audit Group
- ACTACC Linkperson network
- AI (OpenAI, Canvas, Dall-E used for image generation)



# Define Vasoplegia in Cardiac Surgery



## VANCS (2017) (SCA)

MAP<65mmHg, CI >2.2 l/min/m<sup>2</sup>  
At least 1000ml fluid challenge



## ATHOS II (2017)

CI >2.3 l/min/m<sup>2</sup> or ScVO<sup>2</sup> > 70%  
And  
MAP 55-70mmHg + 25ml/kg preceded  
24h  
On Norad >0.2mcg/kg/min

**1<sup>st</sup> October 2024- 31<sup>st</sup> October 2024**



## **Patients with suspected vasoplegia in the perioperative period**

## **Patients that received 'rescue' therapies for vasoplegia**

### **Who were the patients investigated ?**


**Patients suspected of perioperative vasoplegia within the first 48h of undergoing cardiac surgery ( from induction of anaesthesia)**

### **What are the objectives?**

- Characteristics of perioperative vasoplegia in UK cardiac surgical patients
- What proportion of patients receive rescue therapies for vasoplegia?
- What is the association of vasoplegia and clinical outcomes including 30-day mortality, ICU stay and new RRT


### **The triggers for case report:**

- Noradrenaline (  $\geq 0.2 \text{ mcg/kg/min}$  ) \*  
OR
  - >1 Vasopressor (noradrenaline and vasopressin)\*  
OR
  - Administration of rescue pharmacological agents for vasoplegia such as:
    - Methylene blue
    - Hydroxocobalamin (Cyanokit)
    - Ascorbic acid/Thiamine (Pabrinex)
    - Vitamin C
    - Cytokine Adsorber (i.e Cytosorb)
- \* > 1 hour administration



# Response Rate 57%

## UK Cardiac Centres



# Location at Time of Trigger



**Intensive Care**  
**71.8%**



**Operating Theatre**  
**28.2%**



## Induction of anaesthesia

Time Lag


Trigger

Count: 118 patients

Median: 9.0 hours

IQR: 6.2 – 13.3 hours

# Inclusion Trigger



# Incidence analysis



Overall=

(Vasopressor+ Rescue therapy) 125

Total cases October 24 (1675)


7.5%

NACSA 2023/2024:  
Average 2218  
operations/month

Subcohort incidence=

Number of patients fulfilling criteria/Number of patients with  
haemodynamic values or ScVO<sub>2</sub> available

# Incidence Analysis



Overall: 7.5%

Sub-cohorts

61 patients (monitoring data)

Full Haemodynamic: 58%

ATHOS II(ScVO<sub>2</sub>): 40%

Vasoplegia Merged: 59%

Remaining 89



# Patient Characteristics


Female 24%  
Male 76%

Age 67y (56-74)  
BMI : 28 kg/m<sup>2</sup> (23-31)  
Euroscore: 4.5 (2.2-10.4)

	Median	25-75th Centile
Hb (g/dl)	126	106-141
WCC nx 10 <sup>9</sup>	8	6-10
CRP (mg/l)	8	3-21
Creatinine	93	78-118
HbA1c	43	37-50


- CKD eGFR<60 ml/min/1.73m<sup>2</sup> 33% (42 patients)
- Type 2 DM 47% (60 Patients)
- Endocarditis 15.2%(19 patients)

# Preoperative Medications (Within 48h of Sx)






# Preoperative support





# Preoperative support



### Single valve surgery



31 24.8%

### Double valve surgery




15 12.0%

### CABG off pump



4 3,2%

### CABG on pump



26 20.8%

### CABG + valve



14 11.2%

### LVAD implantation



3 2,4%

### Major aortic surgery



16 12.8 %

### Other

(HOCM surgery, ASD repair, VSD)



13 10.4%


### Heart transplant



2 1,6%




# Surgical Characteristics







# CO monitor used in 56%

**CO Monitoring Used**





# Physiological Parameters



**CH1:Art**

**CH2:CVP**




Vasodilated to touch

- Vasoplegia Cohort: 90%  
Remaining: 58%

### Remaining Cohort

CRT <2s

41.9%




### Vasoplegia Cohort

CRT <2s

10%



# Fluid Balance on trigger



Median Volumes




Overall  
1430ml (720-2978)

Vasoplegia: 1836(800-3000)


Remaining:  
1402 (681-2500)



# TOE examination




# Pharmacological Support






Dose Distribution for Selected Drugs (Users Only)


Drug = Adrenaline (mcg/kg/min)




Drug = Milrinone (mcg/kg/min)



Drug = Noradrenaline (mcg/kg/min)




Drug = Vasopressin (units/min)



## Pharmacological Support

- Noradrenaline  
mcg/kg/min: 0.22  
(0.19-0.29)
- Adrenaline  
mcg/kg/min: 0.05  
(0.02-0.1)
- Vasopressin units/min:  
0.03 (0.025-0.04)
- Milrinone mcg/kg/min:  
0.2 (0.1-0.23)

# Other support @ Trigger




**MCS 20% (25)**  
**IABP 88% (22)**  
**VA ECMO 8% (2)**  
**VAD 2**



# Steroid and Rescue Therapies



## Use of Rescue Therapies by Cohort





# Potential Vasodilators





NO 9.6% (12 )  
Prostacyclin 0.8% (1)



Amiodarone 8% (11)



# Patient Outcomes



ICU Mortality 17.6%  
(22/125)

ICU LOS Median 6 (4-16)  
Hospital LOS 13 (8-27)



# Limitations

## Selection bias

- inclusion based on vasopressor thresholds and rescue therapy
- No control group by design (Audit)

Definitions of Vasoplegia  
highly dependent on monitoring

Designed as snapshot audit (short window)

No adjustment for confounding ( no multivariate)

May be missing mixed shock states



# Conclusions

Vasoplegia rates compatible with wider literature 5%-20% or Higher Risk groups (30-50%)

Diagnosis linked to monitoring but clinical signs may help

Most cases triggered by vasopressor criteria/ Rescue therapy is rare

Inclusion criteria identified a high risk cohort (17-19% Mortality)

CAPTIVE  
Cardiogenic Shock(MCS) +  
Vasoplegia



**ACTACC**

Association for Cardi thoracic Anaesthesia  
and Critical Care

Thank you

*Special thank you to all contributors  
to the audit and the ACTACC  
linkperson network*